GO:0006027 glycosaminoglycan catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006027 (glycosaminoglycan catabolic process) describes the biochemical breakdown of glycosaminoglycans (GAGs), linear polysaccharides made of repeating disaccharide units.
• GAG catabolism is essential for extracellular matrix turnover and is tightly linked to tissue remodeling, inflammation, and disease.
• Key enzymes include lysosomal exoglycosidases and sulfatases; their deficiency causes mucopolysaccharidoses.
• GAG fragments generated by catabolism can act as signaling molecules influencing chemokine activity and macrophage metabolism.
• Dysregulated GAG catabolism contributes to osteoarthritis, diabetic wound healing, and cutaneous mucinoses.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of GAG catabolic genes in human disease.
Description
Glycosaminoglycans (GAGs) are linear polysaccharides composed of repeating disaccharide units that are covalently attached to core proteins to form proteoglycans. The glycosaminoglycan catabolic process (GO:0006027) encompasses the chemical reactions and pathways that degrade these molecules into smaller fragments and monosaccharides. This process is fundamental for extracellular matrix (ECM) remodeling, turnover of proteoglycans, and recycling of GAG building blocks. In humans, impaired GAG catabolism leads to lysosomal storage disorders known as mucopolysaccharidoses, while altered GAG turnover is implicated in osteoarthritis, chronic wounds, and skin pathologies. Understanding the enzymes, cofactors, and regulatory mechanisms of GAG catabolism is therefore critical for developing therapies targeting ECM-related diseases. Recent studies highlight that GAG fragments can modulate immune cell metabolism and chemokine functions, expanding the biological significance of this catabolic process beyond simple degradation.
glycosaminoglycan catabolic process At A Glance
| GO ID | GO:0006027 |
|---|---|
| GO term | glycosaminoglycan catabolic process |
| Ontology | biological_process |
| Synonym | glycosaminoglycan breakdown; glycosaminoglycan catabolism; glycosaminoglycan degradation |
| Major function | Breakdown of glycosaminoglycans into smaller fragments and monosaccharides |
| Cellular location | Lysosome (for most GAG-degrading enzymes) |
| Key enzymes | Exoglycosidases, sulfatases, hyaluronidases |
| Associated diseases | Mucopolysaccharidoses, osteoarthritis, diabetic wound healing impairment |
What Is GO:0006027?
GO:0006027, glycosaminoglycan catabolic process, is defined as the chemical reactions and pathways resulting in the breakdown of glycosaminoglycans, which are linear polysaccharides composed of repeating disaccharide units. This process includes the stepwise removal of sulfate groups and sugar residues by specific hydrolases and sulfatases, ultimately yielding monosaccharides and sulfate.
Why Is glycosaminoglycan catabolic process Important in Cell Biology?
Glycosaminoglycan catabolism is vital for maintaining ECM homeostasis, as it controls the turnover of proteoglycans and the release of bioactive GAG fragments. Defects in this process cause lysosomal storage diseases and contribute to degenerative joint diseases and impaired tissue repair. Moreover, GAG degradation products can influence chemokine gradients and macrophage metabolism, linking GAG catabolism to immune regulation and inflammation.
• Maintains extracellular matrix turnover and tissue remodeling.
• Prevents accumulation of undegraded GAGs in lysosomes, which causes mucopolysaccharidoses.
• Generates GAG fragments that modulate chemokine activity and immune cell recruitment.
• Regulates macrophage glucolipid metabolism during diabetic wound repair.
• Its dysregulation is implicated in osteoarthritis progression.
• Altered GAG catabolism contributes to cutaneous mucinoses.
• Provides targets for enzyme replacement therapies in lysosomal storage disorders.
• Serves as a model for studying proteoglycan turnover and ECM dynamics.
• Influences skin hydration and collagen network via GAG turnover.
• Can be studied using CRISPR screens to identify novel catabolic regulators.
What Happens During glycosaminoglycan catabolic process?
Initiation of GAG degradation
In simple terms: The breakdown of GAGs starts when enzymes cut the long sugar chains into smaller pieces.
Glycosaminoglycan catabolism begins with the action of endoglycosidases such as hyaluronidases, which cleave internal glycosidic bonds within GAG chains, generating oligosaccharides. These initial cleavage events are often extracellular or at the cell surface, followed by internalization and delivery to lysosomes.
Lysosomal exoglycosidase action
In simple terms: Inside lysosomes, a series of enzymes remove sugar units one by one from the ends of the fragments.
Once inside lysosomes, exoglycosidases sequentially remove terminal sugars from the non-reducing end of GAG oligosaccharides. Each enzyme is specific for a particular sugar and linkage, ensuring processive degradation. Deficiencies in these enzymes lead to accumulation of partially degraded GAGs, characteristic of mucopolysaccharidoses.
Sulfate removal by sulfatases
In simple terms: Sulfate groups must be removed before some sugars can be cleaved, and specialized enzymes do this.
Sulfatases remove sulfate esters from GAGs, a prerequisite for subsequent glycosidase action. For example, iduronate-2-sulfatase and heparan-N-sulfatase are critical for heparan sulfate and dermatan sulfate degradation. Their deficiency causes several types of mucopolysaccharidoses.
Generation of bioactive fragments
In simple terms: The breakdown process does not just destroy GAGs; it also creates small pieces that can send signals to cells.
Partial degradation of GAGs releases oligosaccharides that can bind to chemokines such as CXCL8 and CXCL12, modulating their activity and gradient formation. These fragments can also reprogram macrophage metabolism, as shown for Andrias davidianus-derived GAGs in diabetic wound repair.
Regulation by cellular metabolism
In simple terms: How cells use energy and nutrients can affect how fast GAGs are broken down.
Recent evidence links GAG catabolism to cellular metabolic states. For instance, lactylation of UGDH suppresses GAG synthesis and alters nucleocytoplasmic transport, indirectly affecting GAG turnover in osteoarthritis. This crosstalk highlights that catabolism is not merely a constitutive process but can be regulated by metabolic signals.
Key Genes Involved in GO:0006027 glycosaminoglycan catabolic process
The following genes encode enzymes and proteins directly involved in glycosaminoglycan catabolic process, based on published literature and their roles in GAG degradation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HYAL1 | Hyaluronidase that degrades hyaluronan | Studied in cancer and ECM remodeling |
| HYAL2 | Hyaluronidase involved in hyaluronan catabolism | Linked to lysosomal GAG degradation |
| IDS | Iduronate-2-sulfatase removes sulfate from dermatan/heparan sulfate | Deficiency causes MPS II |
| IDUA | Alpha-L-iduronidase cleaves iduronic acid residues | Deficiency causes MPS I |
| GUSB | Beta-glucuronidase removes glucuronic acid | Deficiency causes MPS VII |
| GALNS | N-acetylgalactosamine-6-sulfatase | Deficiency causes MPS IVA |
| ARSB | Arylsulfatase B removes sulfate from dermatan sulfate | Deficiency causes MPS VI |
| NAGLU | Alpha-N-acetylglucosaminidase | Deficiency causes MPS IIIB |
| SGSH | Heparan-N-sulfatase | Deficiency causes MPS IIIA |
| HGSNAT | Heparan-alpha-glucosaminide N-acetyltransferase | Deficiency causes MPS IIIC |
| GNS | N-acetylglucosamine-6-sulfatase | Deficiency causes MPS IIID |
| UGDH | UDP-glucose dehydrogenase, affects GAG synthesis and turnover | Lactylation linked to osteoarthritis |
| CXCL8 | Chemokine modulated by GAG fragments | Inflammation and immune cell recruitment |
| CXCL12 | Chemokine binding GAGs | Cell migration and tissue repair |
| CTSK | Cathepsin K, protease that can degrade proteoglycans | ECM remodeling in bone and cartilage |
| MMP2 | Matrix metalloproteinase-2, degrades ECM including proteoglycans | Cancer and arthritis models |
| MMP9 | Matrix metalloproteinase-9 | Inflammation and wound healing |
| TGFB1 | Regulates ECM synthesis and turnover | Fibrosis and wound healing |
How Is glycosaminoglycan catabolic process Regulated?
Glycosaminoglycan catabolic process is regulated at multiple levels. Transcriptionally, enzymes such as HYAL1 and sulfatases can be induced by inflammatory cytokines. Post-translationally, sulfatase activities require activation by formylglycine-generating enzyme. Metabolically, lactylation of UGDH alters GAG synthesis and indirectly influences catabolism. Additionally, GAG fragments themselves can feedback to modulate chemokine signaling and macrophage metabolism.
glycosaminoglycan catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IDUA | Mucopolysaccharidosis I | IdUA knockout mice or patient fibroblasts |
| IDS | Mucopolysaccharidosis II | IDS knockout cell lines |
| UGDH | Osteoarthritis | UGDH lactylation mutants in chondrocytes |
| CXCL8 | Inflammation | CXCL8 knockout macrophages |
| HYAL1 | Cancer ECM remodeling | HYAL1 overexpression in tumor cells |
Mucopolysaccharidoses
Mucopolysaccharidoses are a group of inherited lysosomal storage disorders caused by deficiencies in enzymes that degrade glycosaminoglycans. Accumulation of undegraded GAGs leads to multi-organ dysfunction, including skeletal abnormalities, cardiac issues, and neurological impairment. Enzyme replacement therapy and hematopoietic stem cell transplantation are used for several types.
Osteoarthritis
Osteoarthritis involves progressive degradation of cartilage ECM, rich in GAGs. Recent work shows that UGDH lactylation suppresses GAG synthesis and activates MAPK signaling, aggravating osteoarthritis. This highlights the balance between GAG synthesis and catabolism in joint health.
Diabetic wound healing
Impaired wound healing in diabetes is associated with altered GAG metabolism. Andrias davidianus-derived GAGs have been shown to reprogram reparative macrophage glucolipid metabolism, promoting diabetic wound repair. This suggests that modulating GAG catabolism or its products could be therapeutic.
Cutaneous mucinoses
Cutaneous mucinoses are characterized by excessive deposition of mucin, which contains GAGs, in the skin. Abnormal GAG catabolism may contribute to mucin accumulation, although the exact mechanisms remain under investigation.
From glycosaminoglycan catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IDUA impair GAG catabolism? | IDUA knockout cell line (e.g., HEK293) |
| Does a point mutation in IDS affect enzyme activity? | IDS point-mutation knock-in via CRISPR |
| Can tagged HYAL1 track lysosomal localization? | HYAL1 knock-in with fluorescent tag |
| Does UGDH lactylation alter GAG turnover? | UGDH point-mutation (lactylation site) knock-in |
| Does overexpression of GUSB rescue GAG accumulation? | GUSB overexpression in MPS VII fibroblasts |
| Which genes regulate GAG catabolism in macrophages? | CRISPR library screening in macrophage cell line |
How to Study the glycosaminoglycan catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Specific GAG-degrading enzyme activity | Diagnosis of MPS, validation of KO |
| LC-MS | GAG disaccharide composition and abundance | Quantifying catabolic flux |
| Dimethylmethylene blue assay | Total sulfated GAG content | Screening for catabolic defects |
| CRISPR knockout screen | Genes required for GAG catabolism | Identifying novel regulators |
| Immunofluorescence | Localization of GAGs and enzymes | Lysosomal tracking |
| Western blot | Protein expression of catabolic enzymes | Validating overexpression or KO |
| qRT-PCR | mRNA levels of GAG-degrading enzymes | Transcriptional regulation studies |
| Flow cytometry | GAG content on cell surface | Immune cell GAG turnover |
Enzymatic activity assays
Enzymatic activity assays using fluorogenic or chromogenic substrates measure the activity of specific GAG-degrading enzymes such as iduronidase or sulfatases. These assays are essential for diagnosing mucopolysaccharidoses and validating CRISPR-edited cell lines.
Glycosaminoglycan quantification
Total GAG content can be quantified using colorimetric assays (e.g., dimethylmethylene blue) or liquid chromatography-mass spectrometry (LC-MS) to assess catabolic flux. These methods are used to evaluate the impact of gene knockouts or point mutations on GAG turnover.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate GAG catabolism. For example, screening in macrophages treated with GAGs can reveal modifiers of glucolipid metabolism. Hits are validated by targeted knockout and GAG degradation assays.
Imaging and immunohistochemistry
Fluorescently tagged GAGs or antibodies against GAG neoepitopes can visualize catabolic processing in cells and tissues. Live-cell imaging of lysosomal enzymes tagged with CRISPR knock-in enables dynamic tracking of GAG degradation.
How CRISPR Can Be Used to Study GO:0006027 glycosaminoglycan catabolic process
Knockout
CRISPR knockout of GAG catabolic genes such as IDUA or IDS in cell lines (e.g., HEK293, fibroblasts) creates models of mucopolysaccharidoses. These knockouts accumulate undegraded GAGs and can be used to test enzyme replacement or gene therapy.
Point Mutation
Point mutations in genes like IDS or UGDH can be introduced via CRISPR to mimic patient-specific missense mutations. Such models help dissect the impact of single amino acid changes on enzyme activity and GAG catabolism.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous GAG enzyme loci (e.g., HYAL1) allows real-time tracking of enzyme localization and trafficking in lysosomes. This approach is valuable for studying catabolic dynamics.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression of GAG-degrading enzymes can rescue GAG accumulation in disease models. For example, overexpressing GUSB in MPS VII cells restores catabolic capacity.
How EDITGENE Supports glycosaminoglycan catabolic process Research
Researchers studying glycosaminoglycan catabolic process-related genes often need to determine whether a candidate gene is causally involved in GAG turnover, lysosomal function, or disease progression. EDITGENE provides CRISPR-based cell model services to enable such causal studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for glycosaminoglycan catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GNS Knockout HEK293 Cell Line | EDJ-KQ2252 | Human | 2799 | Details Get a Quote |
| IDUA Knockout HEK293 Cell Line | EDJ-KQ2272 | Human | 3425 | Details Get a Quote |
| GUSB Knockout HEK293 Cell Line | EDJ-KQ4034 | Human | 2990 | Details Get a Quote |
| IDS Knockout HEK293 Cell Line | EDJ-KQ4973 | Human | 3423 | Details Get a Quote |
| HYAL2 Knockout HEK293 Cell Line | EDJ-KQ5631 | Human | 8692 | Details Get a Quote |
| SGSH Knockout HEK293 Cell Line | EDJ-KQ5746 | Human | 6448 | Details Get a Quote |
| HYAL4 Knockout HEK293 Cell Line | EDJ-KQ8065 | Human | 23553 | Details Get a Quote |
| GNS Knockout A-549 Cell Line | EDJ-KQ23935 | Human | 2799 | Details Get a Quote |
| GNS Knockout HCT 116 Cell Line | EDJ-KQ23936 | Human | 2799 | Details Get a Quote |
| GNS Knockout HeLa Cell Line | EDJ-KQ23937 | Human | 2799 | Details Get a Quote |
| IDUA Knockout A-549 Cell Line | EDJ-KQ23983 | Human | 3425 | Details Get a Quote |
| IDUA Knockout HCT 116 Cell Line | EDJ-KQ23984 | Human | 3425 | Details Get a Quote |
| IDUA Knockout HeLa Cell Line | EDJ-KQ23985 | Human | 3425 | Details Get a Quote |
| SGSH Knockout A-549 Cell Line | EDJ-KQ29148 | Human | 6448 | Details Get a Quote |
| SGSH Knockout HCT 116 Cell Line | EDJ-KQ29149 | Human | 6448 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About glycosaminoglycan catabolic process
What is glycosaminoglycan catabolic process?
It is the biochemical breakdown of glycosaminoglycans, linear polysaccharides, into smaller fragments and monosaccharides, primarily in lysosomes.
What genes are involved in glycosaminoglycan catabolic process?
Key genes include IDUA, IDS, GUSB, GALNS, ARSB, NAGLU, SGSH, HGSNAT, GNS, HYAL1, and HYAL2, among others.
What diseases are linked to defects in GAG catabolism?
Mucopolysaccharidoses, osteoarthritis, diabetic wound healing impairment, and cutaneous mucinoses.
Where does glycosaminoglycan catabolism occur in the cell?
Most GAG degradation occurs in lysosomes, where specific exoglycosidases and sulfatases reside.
How is glycosaminoglycan catabolic process regulated?
It is regulated by enzyme expression, post-translational modifications like lactylation, and metabolic signals.
What are the products of GAG catabolism?
The process yields monosaccharides, sulfate, and small oligosaccharides that can have signaling functions.
Can CRISPR be used to study GAG catabolism?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable causal studies of GAG-degrading genes.
What methods measure GAG catabolism?
Enzymatic activity assays, LC-MS, dimethylmethylene blue assay, and CRISPR screens are commonly used.
Why is GAG catabolism important for wound healing?
GAG fragments can reprogram macrophage metabolism and promote repair, as shown in diabetic wound models.
What is the role of UGDH in GAG catabolism?
UGDH affects GAG synthesis and its lactylation suppresses GAG production, indirectly influencing catabolism in osteoarthritis.
Conclusion
Glycosaminoglycan catabolic process (GO:0006027) is a fundamental biological pathway that controls ECM turnover and produces bioactive fragments. Its dysregulation underlies lysosomal storage disorders, osteoarthritis, and impaired wound healing. CRISPR-based models are powerful tools to dissect the genetic and mechanistic basis of GAG catabolism, offering new avenues for therapeutic intervention.
References
- 1. Cambier S et al.. 2023. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.. Cell Mol Immunol 20(3):217-251 PMID: 36725964
- 2. Lan W et al.. 2025. UGDH Lactylation Aggravates Osteoarthritis by Suppressing Glycosaminoglycan Synthesis and Orchestrating Nucleocytoplasmic Transport to Activate MAPK Signaling.. Adv Sci (Weinh) 12(20):e2413709 PMID: 40150862
- 3. Kogut MM et al.. 2022. Modeling glycosaminoglycan-protein complexes.. Curr Opin Struct Biol 73:102332 PMID: 35152187
- 4. Asserin J et al.. 2015. The effect of oral collagen peptide supplementation on skin moisture and the dermal collagen network: evidence from an ex vivo model and randomized, placebo-controlled clinical trials.. J Cosmet Dermatol 14(4):291-301 PMID: 26362110
- 5. Kresse H et al.. 1994. Small proteoglycans.. EXS 70:73-100 PMID: 8298253
- 6. Ricard-Blum S et al.. 2022. Glycosaminoglycan interaction networks and databases.. Curr Opin Struct Biol 74:102355 PMID: 35306322
- 7. Truhan AP et al.. 1986. The cutaneous mucinoses.. J Am Acad Dermatol 14(1):1-18 PMID: 2419372
- 8. Yang P et al.. 2025. Andrias davidianus Derived Glycosaminoglycans Direct Diabetic Wound Repair by Reprogramming Reparative Macrophage Glucolipid Metabolism.. Adv Mater 37(12):e2417801 PMID: 39967388
